Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. (2001)
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817.
Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Lawson JA, FitzGerald GA. (2002)
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541.
Grosser T, Yusuff S, Cheskis E, Pack MA, FitzGerald GA. (2002)
Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci USA 99: 8418-8423.
Egan K, Smyth E, Fries S, Rader D, FitzGerald GA. (2004)
Prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957.
Cheng Y, Wang M, Yu Y, Lawson J, Funk C, FitzGerald GA. (2006)
Cyclooxygenases, mPGES-1 and cardiovascular function. J Clin Invest 116: 1391-1399.
Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, FitzGerald GA. (2006)
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci 103: 14507-14512.
Wang D, Patel V, Gao E, Rong Z, Levin M, Yu Z, Ferrari V, Lu MM, Xu J, Zhang H, Hui Y, Lawson J,Yi Y, FitzGerald GA. (2009)
Cardiomyocyte cyclooxygenase –2 influences cardiac rhythm and function. Proc Natl Acad Sci 106: 7548-7552.
Song, W., Paschos, G., Fries, S., Reilly, M., Rokach, J., Chang, C.-T., Patel, P.,Lawson, J. and FitzGerald, G.A. (2009).
Novel EPA derived F3 isoprostanes as biomarkers of lipid peroxidation. J. Biol. Chem. 284: 23636-23643.
Yu Y, Lucitt M, Stubbe J, Cheng Y, Jensen BL, Hansen B, Smyth E, FitzGerald GA. (2009)
Prostaglandin F²α elevates blood pressure and promotes atherogenesis. Proc Natl Acad Sci 106: 7985-7990.
Hui Y, Ricciotti E, Crichton I, Yu Z, Wang D, Stubbe J, Wang M, Puré E, FitzGerald GA. (2010)
Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 121(24): 2654-2660.
McNamara P, Seo S-B, Rudic RD, Sehgal A, Chakravarti D, FitzGerald GA. (2001)
Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: A humoral mechanism to reset a peripheral clock. Cell 105: 877-889.
Rudic RD, McNamara P, Curtis AM, Boston RC, Panda S, Hogenesch JB, FitzGerald GA. (2004)
BMAL1 and CLOCK, two essential components of the circadian clock are involved in glucose homeostasis. PLOS Biol 2: 1893-1899.
Curtis A, Cheng Y, Kapoor S, Reilly D, Price TS, FitzGerald GA. (2007)
Circadian variation in blood pressure and the vascular response to asynchronous stress. Proc Natl Acad Sci 104: 3450-3455.
Baggs JE, Price TS, DiTacchio L, Panda S, FitzGerald GA, Hogenesch JB (2009)
Network features of the mammalian circadian clock. PLoS Biol 7(3): e52.
Paschos G. and FitzGerald G.A. (2010).
Circadian clocks and vascular function. Circ. Res. 106(5):833-41.
Skarke C and FitzGerald GA. (2010)
Training translators for smart drug discovery. Sci Transl Med 2(26): 26cm12.
Our laboratory has two areas of interest – prostanoid biology and the role of peripheral molecular clocks in cardiovascular biology, metabolism and aging. Perhaps the distinguishing feature of our groups is that we pursue interdisciplinary translational science with a focus on therapeutics. Thus, we work in different model systems – mammalian cells, worms, fish and mice – but also in humans. Ideally we develop quantitative approaches that can be projected from our experiments in the model systems to guide elucidation of drug action in humans. To this end, we have long utilized mass spectrometry, initially to target the arachidonate derived lipidome, but more latterly also the proteome.
Currently, we are interested in several aspects of prostanoid research. We utilize a remarkably broad array of mutant mice to elucidate the biology of the two COX enzymes and the prostanoid receptors. We are particularly interested in the comparative efficacy and safety of pharmacological inhibition of COXs versus the microsomal PGE synthase– 1. We are interested in the potentially countervailing actions of prostanoids on stem cell differentiation and in elucidating the broader cardiovascular biology of prostaglandins D2 and F2α . Finally, besides inhibitors of mPGES–1 we are interested in the translational therapeutics of various receptor antagonists, aspirin and fish oils.